adoptive immunotherapy with lymphokine-activated killer cells and recombinant interleukin 2 ( il 2 ) can produce significant reduction of visceral metastases in tumor-bearing mice and , as shown recently , in humans with disseminated cancer .
C0021756
recombinant
C0086418
humans